Donald J Trump (R) Sells Danaher (DHR) Stock

Donald J Trump recently disclosed a sale of Danaher Corporation (NYSE: DHR) stock. According to a periodic transaction report, the Republican politician sold a stake valued between $15,001 and $50,000. The trade took place on May 22, 2026, though the public did not learn of the move until the filing was reported on July 1, 2026.

This sale occurred on the same day Trump reported several other divestments. On May 22, 2026, he also sold shares in Tyler Technologies, Ecolab, Repligen Corporation, and Netflix. While those trades were mostly in the $1,001 to $15,000 range, the Danaher transaction involved a larger dollar amount. These disclosures are required under the STOCK Act, which mandates that high-ranking officials report their financial trades shortly after they occur.

Danaher Stock Performance

On Wednesday, Danaher shares were priced at $190.79. The stock has traded in a wide range over the last year, reaching as high as $242.80 and dropping as low as $160.93. At current levels, the company carries a price-to-earnings (P/E) ratio of 41.27, which tells us how much investors are paying for each dollar of profit. Its forward P/E, which looks at expected future earnings, is 24.90. The stock is currently trading below its 50-day moving average of $213.32 and its 200-day moving average of $201.33.

Recent Earnings and Growth

In its latest financial reporting, Danaher posted annual revenue of $25.11 billion. This represents a 5.5% increase in sales compared to the previous period. The company remains profitable, reporting a net margin of 15.95% and a return on equity of 7.61%. Investors looking ahead should note that the company is scheduled to release its next set of quarterly results on October 21, 2026.

Dividend Information

Danaher continues to return capital to its shareholders through a regular dividend. The company offers a dividend yield of 0.69%. Its payout ratio stands at 0.2567, meaning it uses roughly 26% of its earnings to cover these payments, leaving the rest for operations or other investments.

Analysts Set New Price Targets

Wall Street researchers generally have a positive outlook on the company. There are 22 analysts covering the stock with a consensus recommendation of "strong buy." On October 13, 2026, Morgan Stanley maintained its Overweight rating and set a $240.00 price target. That same day, TD Cowen kept its Buy rating with a $255.00 target. Other recent updates include Barclays maintaining an Overweight rating with a $255.00 target on October 7, 2026, and RBC Capital reiterating an Outperform rating with a $250.00 target on October 5, 2026. Guggenheim also maintained a Buy rating on October 1, 2026, with a $250.00 price target.

About Danaher Corporation

Danaher Corporation is a global science and technology company that creates tools for the medical and industrial sectors. It operates through three main wings: Biotechnology, Life Sciences, and Diagnostics. The company produces everything from mass spectrometers and microscopes to the clinical instruments hospitals use to diagnose diseases. Based in Washington, D.C., the firm has grown into a massive healthcare player with about 58,000 employees since it changed its name from Diversified Mortgage Investors in 1984.

What to Watch

The gap between the transaction date in May and the July filing is common for these types of disclosures. Investors often track these reports to see where political figures are moving their money, though these filings are backward-looking and may not show what the person owns today. The next major catalyst for the stock will likely be the earnings report coming in October.